Omalizumab Provides Long-term Control in Patients with Moderate-to-severe Allergic Asthma

Abstract

Buhl R, Soler M, Matz J, et al. Eur Respir J. 2002;20:73–78 Purpose of the Study. To examine the ability of omalizumab, an anti-immunoglobulin E (anti-IgE) agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma. Study Population. Four hundred eighty-three patients with moderate-to-severe allergic asthma maintained… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.